细胞生物学
移植
胚胎干细胞
诱导多能干细胞
干细胞
再生医学
电池类型
小岛
生物
细胞分化
细胞
免疫学
功能(生物学)
细胞疗法
间充质干细胞的临床应用
内生
成体干细胞
诱导干细胞
癌症研究
定向微分
化学
巨噬细胞
细胞功能
科斯尔
细胞培养
作者
Bruno F.A. Freitas,Sean A. Fox,Paul C. Orban,Jane Velghe,Majid Mojibian,Derek Dai,Galina Soukhatcheva,Francis C. Lynn,Megan K. Levings,C Verchere
出处
期刊:Science Advances
[American Association for the Advancement of Science]
日期:2026-06-12
卷期号:12 (24): eaed4221-eaed4221
标识
DOI:10.1126/sciadv.aed4221
摘要
The generation of insulin-producing, stem cell–derived β cells (SC-β cells) from human embryonic or induced pluripotent stem cells holds promise for treating type 1 diabetes. Transplantation of SC-β cells is already in clinical testing, but generating mature cells with insulin-secreting properties similar to endogenous cells has been challenging. Given that macrophages are essential for islet development, we hypothesized that they could enhance SC-β cell differentiation and function. We coaggregated autologous SC-macrophages that were either unpolarized (SC-M Unp ) or polarized to inflammatory (SC-M Inf ) or regenerative (SC-M Reg ) states during stage 7 of SC-β cell differentiation. SC-M Regs improved maturity marker expression, glucose-stimulated insulin secretion, and metabolic activity in SC-β cells. Transplantation of SC-β cells coaggregated with SC-M Regs into diabetic mice normalized glycemia significantly faster than transplantation of SC-β cells alone. The finding that addition of macrophages during SC-β differentiation accelerates functional maturation represents a notable advance in the production of SC-β cells as a regenerative cell therapy for type 1 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI